Dipan Mehta of Elixir Equities offers a selective outlook, favoring NBFCs and pharma while cautioning on metals and avoiding certain largecaps. He sees strength in diversified NBFCs and potential in solar despite current underperformance, but advises patience in real estate and a clear avoid on tobacco stocks like ITC.
Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, Biocon
Biocon CEO Siddharth Mittal outlines the company’s strategy in the competitive GLP-1 market. Focusing on liraglutide’s launch in the US and Europe, he highlights opportunities